U.S. markets closed

Charles River Laboratories International, Inc. (CRL)

NYSE - Nasdaq Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
240.13+7.57 (+3.26%)
Al cierre: 04:00PM EDT
240.13 +0.01 (+0.00%)
Fuera de horario: 04:05PM EDT

Charles River Laboratories International, Inc.

251 Ballardvale Street
Wilmington, MA 01887
United States
781 222 6000
https://www.criver.com

Sector(es)Healthcare
IndustriaDiagnostics & Research
Empleados a tiempo completo20,400

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. James C. Foster J.D.CEO, President & Chairman2.66MN/D1951
Ms. Flavia H. PeaseCorporate Executive VP & CFO1.66MN/D1973
Ms. Birgit GirshickCorporate Executive VP & COO1.28M464.88k1970
Mr. Joseph W. LaPlumeCorporate Executive Vice President of Corporate Development & Strategy928.36k262.98k1974
Mr. William D. BarboCorporate Executive Vice President of Community Relations1M399.92k1961
Mr. Michael Gunnar KnellCorporate Senior VP & Chief Accounting OfficerN/DN/D1977
Prof. Julie Frearson Ph.D.Corporate Senior VP & Chief Scientific OfficerN/DN/DN/D
Mr. Mark MintzCorporate Senior VP & Chief Information OfficerN/DN/DN/D
Todd SpencerCorporate Vice President of Investor RelationsN/DN/DN/D
Mr. Matthew L. DanielCorporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance OfficerN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Gestión corporativa

La calificación ISS Governance QuickScore de Charles River Laboratories International, Inc. a partir del 1 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 6; Derechos del accionista: 8; Compensación: 7.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.